Alpha Cognition, Inc. Attends the BIO Digital Partnering Event This Week
June 8, 2020
Vancouver, BC (Canada) June 8, 2020 –Alpha Cognition Inc. (ACI), a clinical stage neurodegenerative disease company, has announced it is participating in this year’s BIO Digital Partnering Event, June 8th-12th. ACI is looking forward to a week full of introductory meetings, from morning to night, with companies from all over the world. For those companies ACI is not able to connect with during this week’s virtual conference, please take a few minutes to review information about the company and its products.
To each of the companies ACI will be meeting with, we look forward to a productive event!
For additional information about the Company and its research programs, visit the Company’s website at http://www.alphacognition.com.
About Alpha Cognition Inc. – Alpha Cognition Inc. (ACI) is engaged in neurological disease research and has developed programs in Alzheimer’s Disease and amyotrophic lateral sclerosis (ALS).
- Alpha-1062 is a patented new chemical entity that has shown efficacy in preclinical and recently completed human clinical trials. It is being developed as a new generation acetylcholine esterase inhibitor (AChEI) with minimal gastrointestinal side effects and new routes of administration. Alpha-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.
- Alpha-602 (Progranulin) is a natural protein that is expressed in several cell types in the central nervous system and in peripheral tissues. Alpha-602 regulates cell survival and certain inflammatory processes. The protein plays a major role in regulating lysosomal function and microglial responses to disease. Its use in the treatment of ALS has been patented by ACI.
Or write to:
Alpha Cognition Inc.
439 Helmcken Street,
Vancouver, B.C. V6B 2E6